I-Mab (IMAB) Revenue & Revenue Breakdown
I-Mab Revenue Highlights
Latest Revenue (Y)
$27.64M
Latest Revenue (Q)
$1.10M
Main Segment (Y)
Licensing and Collaboration
I-Mab Revenue by Period
I-Mab Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $27.64M | -112.48% |
| 2022-12-31 | $-221.56M | -351.70% |
| 2021-12-31 | $88.03M | -94.29% |
| 2020-12-31 | $1.54B | 5042.23% |
| 2019-12-31 | $30.00M | -44.22% |
| 2018-12-31 | $53.78M | 365.39% |
| 2017-12-31 | $11.56M | - |
I-Mab generated $27.64M in revenue during NA 2023, up -112.48% compared to the previous quarter, and up 51.40% compared to the same period a year ago.
I-Mab Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.10M | -61.08% |
| 2023-06-30 | $2.84M | -100.16% |
| 2022-12-31 | $-1.76B | -22147.83% |
| 2022-06-30 | $8.00M | -100.53% |
| 2021-12-31 | $-1.51B | -198.06% |
| 2020-12-31 | $1.54B | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2019-09-30 | $15.00M | 44.37% |
| 2018-12-31 | $10.39M | -52.80% |
| 2018-09-30 | $22.01M | - |
I-Mab generated $1.10M in revenue during Q4 2023, up -61.08% compared to the previous quarter, and up 0.07% compared to the same period a year ago.
I-Mab Revenue Breakdown
I-Mab Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Supply Of Investigational Products | $10.83M | $28.10M | $47.91M | - |
| Licensing and Collaboration | $16.81M | $-249.66M | $40.12M | - |
| Grant | - | - | - | $10.00M |
I-Mab's latest annual revenue breakdown by segment (product or service), as of Dec 23: Licensing and Collaboration (60.82%), and Supply Of Investigational Products (39.18%).
Quarterly Revenue by Product
| Product/Service | Dec 22 | Jun 22 | Sep 20 |
|---|---|---|---|
| Grant | $18.90M | $10.00M | - |
| Licensing and Collaboration | - | $23.76M | - |
| Supply Of Investigational Products | - | $28.10M | - |
I-Mab's latest quarterly revenue breakdown by segment (product or service), as of Dec 22: Grant (100.00%).
I-Mab Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Dec 22 | Jun 22 | Sep 20 |
|---|---|---|---|
| Grant | $18.90M | $10.00M | - |
| Licensing and Collaboration | - | $23.76M | - |
| Supply Of Investigational Products | - | $28.10M | - |
I-Mab's latest quarterly revenue breakdown by geography, as of Dec 22: Grant (100.00%).
I-Mab Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BGNE | BeiGene | $2.46B | $929.17M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| KYMR | Kymera Therapeutics | $78.59M | $3.74M |
| NRIX | Nurix Therapeutics | $76.99M | $12.59M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| IMAB | I-Mab | $27.64M | $1.10M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| GRCL | Gracell Bio | - | - |
| IMVT | Immunovant | - | - |
| ERAS | Erasca | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| AKRO | Akero Therapeutics | - | - |
IMAB Revenue FAQ
What is I-Mab’s yearly revenue?
I-Mab's yearly revenue for 2023 was $27.64M, representing a decrease of -112.48% compared to 2022. The company's yearly revenue for 2022 was $-222M, representing a decrease of -351.70% compared to 2021. IMAB's yearly revenue for 2021 was $88.03M, representing a decrease of -94.29% compared to 2020.
What is I-Mab’s quarterly revenue?
I-Mab's quarterly revenue for Q4 2023 was $1.1M, a -61.08% decrease from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q4 2021). The company's quarterly revenue for Q2 2023 was $2.84M, a -100.16% decrease from the previous quarter (Q4 2022), and a -99.82% decrease year-over-year (Q4 2020). IMAB's quarterly revenue for Q4 2022 was $-1.764B, a -22147.83% decrease from the previous quarter (Q2 2022), and a 0% increase year-over-year (Q3 2020).
What is I-Mab’s revenue growth rate?
I-Mab's revenue growth rate for the last 3 years (2021-2023) was -68.60%, and for the last 5 years (2019-2023) was -7.85%.
What are I-Mab’s revenue streams?
I-Mab's revenue streams in c 23 are Supply Of Investigational Products, and Licensing and Collaboration. Supply Of Investigational Products generated $10.83M in revenue, accounting 39.18% of the company's total revenue, down -61.46% year-over-year. Licensing and Collaboration generated $16.81M in revenue, accounting 60.82% of the company's total revenue, down -106.73% year-over-year.
What is I-Mab’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of I-Mab was Licensing and Collaboration. This segment made a revenue of $16.81M, representing 60.82% of the company's total revenue.